These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 39211052)

  • 21. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.
    Espinosa-Carrasco G; Chiu E; Scrivo A; Zumbo P; Dave A; Betel D; Kang SW; Jang HJ; Hellmann MD; Burt BM; Lee HS; Schietinger A
    Cancer Cell; 2024 Jul; 42(7):1202-1216.e8. PubMed ID: 38906155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy.
    Sun L; Ma Z; Zhao X; Tan X; Tu Y; Wang J; Chen L; Chen Z; Chen G; Lan P
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions.
    Hashimoto M; Kamphorst AO; Im SJ; Kissick HT; Pillai RN; Ramalingam SS; Araki K; Ahmed R
    Annu Rev Med; 2018 Jan; 69():301-318. PubMed ID: 29414259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
    McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Potential of T Cell Factor 1 in Sustaining CD8
    Jung S; Baek JH
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33572793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A reservoir of stem-like CD8
    Connolly KA; Kuchroo M; Venkat A; Khatun A; Wang J; William I; Hornick NI; Fitzgerald BL; Damo M; Kasmani MY; Cui C; Fagerberg E; Monroy I; Hutchins A; Cheung JF; Foster GG; Mariuzza DL; Nader M; Zhao H; Cui W; Krishnaswamy S; Joshi NS
    Sci Immunol; 2021 Oct; 6(64):eabg7836. PubMed ID: 34597124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Central memory CD8
    Pais Ferreira D; Silva JG; Wyss T; Fuertes Marraco SA; Scarpellino L; Charmoy M; Maas R; Siddiqui I; Tang L; Joyce JA; Delorenzi M; Luther SA; Speiser DE; Held W
    Immunity; 2020 Nov; 53(5):985-1000.e11. PubMed ID: 33128876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.
    Budimir N; Thomas GD; Dolina JS; Salek-Ardakani S
    Cancer Immunol Res; 2022 Feb; 10(2):146-153. PubMed ID: 34937730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigen dominance hierarchies shape TCF1
    Burger ML; Cruz AM; Crossland GE; Gaglia G; Ritch CC; Blatt SE; Bhutkar A; Canner D; Kienka T; Tavana SZ; Barandiaran AL; Garmilla A; Schenkel JM; Hillman M; de Los Rios Kobara I; Li A; Jaeger AM; Hwang WL; Westcott PMK; Manos MP; Holovatska MM; Hodi FS; Regev A; Santagata S; Jacks T
    Cell; 2021 Sep; 184(19):4996-5014.e26. PubMed ID: 34534464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD8
    Dolina JS; Van Braeckel-Budimir N; Thomas GD; Salek-Ardakani S
    Front Immunol; 2021; 12():715234. PubMed ID: 34354714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD8
    Snell LM; MacLeod BL; Law JC; Osokine I; Elsaesser HJ; Hezaveh K; Dickson RJ; Gavin MA; Guidos CJ; McGaha TL; Brooks DG
    Immunity; 2018 Oct; 49(4):678-694.e5. PubMed ID: 30314757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness.
    Wu T; Ji Y; Moseman EA; Xu HC; Manglani M; Kirby M; Anderson SM; Handon R; Kenyon E; Elkahloun A; Wu W; Lang PA; Gattinoni L; McGavern DB; Schwartzberg PL
    Sci Immunol; 2016 Dec; 1(6):. PubMed ID: 28018990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Road Less Taken: Less Appreciated Pathways for Manipulating CD8
    Pichler AC; Cannons JL; Schwartzberg PL
    Front Immunol; 2022; 13():926714. PubMed ID: 35874734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
    Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
    Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expansion of tumor-reactive CD8
    Morgan DM; Horton BL; Bhandarkar V; Van R; Dinter T; Zagorulya M; Love JC; Spranger S
    Sci Immunol; 2024 Sep; 9(99):eadi3487. PubMed ID: 39270006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1
    Markowitz GJ; Ban Y; Tavarez DA; Yoffe L; Podaza E; He Y; Martin MT; Crowley MJP; Sandoval TA; Gao D; Martin ML; Elemento O; Cubillos-Ruiz JR; McGraw TE; Altorki NK; Mittal V
    Nat Immunol; 2024 Oct; 25(10):1884-1899. PubMed ID: 39327500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.
    Stoltzfus CR; Sivakumar R; Kunz L; Olin Pope BE; Menietti E; Speziale D; Adelfio R; Bacac M; Colombetti S; Perro M; Gerner MY
    Front Immunol; 2021; 12():726492. PubMed ID: 34421928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV
    Li H; Zhu SW; Zhou JJ; Chen DR; Liu J; Wu ZZ; Wang WY; Zhang MJ; Sun ZJ
    J Dent Res; 2023 Jun; 102(6):678-688. PubMed ID: 36883630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.
    Im SJ; Hashimoto M; Gerner MY; Lee J; Kissick HT; Burger MC; Shan Q; Hale JS; Lee J; Nasti TH; Sharpe AH; Freeman GJ; Germain RN; Nakaya HI; Xue HH; Ahmed R
    Nature; 2016 Sep; 537(7620):417-421. PubMed ID: 27501248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response.
    De León-Rodríguez SG; Aguilar-Flores C; Gajón JA; Juárez-Flores Á; Mantilla A; Gerson-Cwilich R; Martínez-Herrera JF; Villegas-Osorno DA; Gutiérrez-Quiroz CT; Buenaventura-Cisneros S; Sánchez-Prieto MA; Castelán-Maldonado E; Rivera Rivera S; Fuentes-Pananá EM; Bonifaz LC
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38969523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.